News
ATHE
1.610
+0.63%
0.010
Alterity Therapeutics to Present at MST Financial Webinar
Barchart · 2d ago
Weekly Report: what happened at ATHE last week (0715-0719)?
Weekly Report · 4d ago
Alterity (ATHE) Up on Interim Data From Advance MSA Study
NASDAQ · 07/18 15:01
Alterity stock climbs 8% on positive Phase 2 data for ATH434-202
Alterity stock climbs 8% on positive Phase 2 data for ATH434-202 in the treatment of multiple system atrophy. 43% of the participants in the study showed improvement in daily living activities. Shares of Alterity Therapeutics climbed 8% Wednesday.
Seeking Alpha · 07/17 16:37
ALTERITY THERAPEUTICS LTD - ATH434 WAS WELL-TOLERATED WITH NO SAFETY SIGNALS DETECTED
Reuters · 07/17 11:25
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
Barchart · 07/17 06:25
Weekly Report: what happened at ATHE last week (0708-0712)?
Weekly Report · 07/15 11:09
Weekly Report: what happened at ATHE last week (0701-0705)?
Weekly Report · 07/08 11:11
Weekly Report: what happened at ATHE last week (0624-0628)?
Weekly Report · 07/01 11:11
Alterity Therapeutics Issues New Employee Options
TipRanks · 07/01 10:55
Weekly Report: what happened at ATHE last week (0617-0621)?
Weekly Report · 06/24 11:19
Weekly Report: what happened at ATHE last week (0610-0614)?
Weekly Report · 06/17 11:10
Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences’ Webinar
Alterity Therapeutics is a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases. David Stamler, M.D., will present a company overview at the MST Access ‘Hidden Gems in Life Sciences’ webinar on June 13, 2024 in Australia.
Barchart · 06/12 18:22
Weekly Report: what happened at ATHE last week (0603-0607)?
Weekly Report · 06/10 11:12
Weekly Report: what happened at ATHE last week (0527-0531)?
Weekly Report · 06/03 11:15
Alterity Therapeutics Unveils Critical Study Data
TipRanks · 05/31 11:00
Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study
Barchart · 05/29 18:21
Weekly Report: what happened at ATHE last week (0520-0524)?
Weekly Report · 05/27 11:20
Alterity Therapeutics Announces Option Cessation
TipRanks · 05/23 10:58
Weekly Report: what happened at ATHE last week (0513-0517)?
Weekly Report · 05/20 11:13
More
Webull provides a variety of real-time ATHE stock news. You can receive the latest news about Alterity Therapeutics Ltd through multiple platforms. This information may help you make smarter investment decisions.
About ATHE
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.